低分子肝素与阿司匹林治疗进展性脑梗死的临床疗效

目的观察低分子肝素与阿司匹林治疗进展性脑梗死的临床疗效。方法选择入院3d内进展性脑梗死患者90例,随机分为抗凝组、联合组和对照组,各30例,抗凝组采用低分子肝素5000U皮下注射,每日2次,口服肠溶阿司匹林100mg每日1次,同时静脉滴注奥扎格雷钠40mg和银杏达莫20mL,均每日1次治疗7d;联合治疗组较抗凝组另外再予依达拉奉30mg静脉滴注每日2次治疗7d;对照组采用口服肠溶阿司匹林100mg每日1次、静脉滴注奥扎格雷钠40mg和银杏达莫20ml,均每日一次治疗7d;治疗前和治疗7d后患者的肝功能、血小板、凝血机制及临床神经功能缺损评分进行评定,比较疗效及安全性。结果 7d后联合治疗组较抗凝组和对照组患者的美国国立卫生院神经功能缺损评分(NIHSS)明显降低(P<0.05),治疗组的临床疗效明显优于抗凝组和对照组(P<0.05)。结论应用低分子肝素联合阿司匹林治疗进展性脑梗死有效。

The Clinical Efficacy of Low Molecular Weight Heparin and Aspirin Treatment of Cerebral Infarction

Objective To observe the therapeutic effect of treating stroke in progression with low molecular heparin and aspirin. Methods 90 patients of stroke in progression were averagely and randomly divided into anticoagulation group, edaravone group and control group. The anticoagulation group was treated with low molecular heparin（10000u/d）, aspirin（100mg/d）, sodium ozagrel（40mg） and ginkgo biloba（20ml/d）. The edaravone group was treated with aspirin（100mg/d）, low molecular heparin（10000u/d）, sodium ozagrel（40mg/d）, ginkgo biloba（20mL/d） and edaravone（60mg/d）. The control group was treated with aspirin（100mg/d）, sodium ozagrel（40mg） and ginkgo biloba（20mL/d）.The time of therapy of each group was 7days. The clinical neurologic impairment score were evaluated to show the therapeutic effect of each group. Results The clinical neurologic impairment score of edaravone group was significantly less than that anticoagulation group and control group（P〈0.05）,which indicated the therapeutic effect edaravone group was significantly superior to that of anticoagulation group and control group（P〈0.05）.Conelusion The applycation of low molecular heparin and aspirin, treating stroke in progression was effective.